Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)